LUPIN

Lupin Ltd.

NSE: LUPIN

BSE: 500257

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

2,460.60+61.0 (+2.54%)

3 Jul, 10:59 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

99.8 / 100

Value Score

53.9 / 100

Price Momentum Score

86.6 / 100

QVM Score

97.2 / 100

Key Metrics

Market Cap

1,09,718 Cr

P/E (TTM)

20.57

P/B

4.89

P/S (TTM)

3.92

EV/EBITDA

13.06

CAPE (5Y)

58.31

ROE (TTM)

26.90

ROCE (TTM)

26.16

ROA (TTM)

15.78

Avg 3Y ROE

20.68

Earnings 3Y CAGR

131.28

Sales 3Y CAGR

18.88

Sales 5Y CAGR

13.02

Debt/Equity

0.29

Consensus TP

2500.00

Strong Buy %

16.67

Promoter Holding

46.86

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Lupin Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Stock is reasonably valued and PE TTM is at a discount to industry median

PE TTM of 20.57 indicates that the stock is reasonably valued on a standalone basis. Discount to industry median P/E is decent at -32.02%

What is P/E Ratio?

Median: 30.26

Value 20.57

-215.443183

Strong price momentum

Price Momentum score of 86.6 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

86.6 / 100

Analysts have been raising forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has increased by 2.65% in the last 3 months, indicating earnings momentum

What is Earnings upgrade (3M)?

High and improving ROE

The company reported strong ROE of 26.9% for 12-month ended 31 Mar 2026 and ROE improved by 605 bps from 1 year ago

What is ROE (FY)?

High and improving operating margin

The company reported strong operating margin of 24.27% for 12-month ended 31 Mar 2026 and operating margin improved by 617 bps from 1 year ago

What is Operating profit margin?

Strong revenue growth and above median growth of industry

The company delivered strong revenue growth of 23.12% for 12-month ended 31 Mar 2026 and the growth was 11.88 percentage points higher than median growth of industry

What is Sales growth (1Y)?

Median: 11.24

Value 23.12

-82.35114662

Strong EPS growth and above median growth of industry

The company delivered strong EPS growth of 62.43% for 12-month ended 31 Mar 2026 and the growth was 54.31 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.29 as on 31 Mar 2026 and Debt to Equity decreased marginally by 0.03 in the last 1 year

What is Debt to Equity?

Company's earnings are of high quality

Earnings quality score of 75.0 indicates that the company's earnings are of high quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

75.0 / 100

Consistently pays dividend

The company has not missed dividend payments once in the last 10 financial years

What is Dividend streak?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Low dividend yield

The company has a low dividend yield of 0.5%

What is Dividend yield?

Neutral

Not enough talking points with neutral stance

Financial Snapshot

See detailed analysis

Multi-year trends for Lupin Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Lupin Ltd. Shareholding Pattern

Quarterly breakdown of Lupin Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Promoter	46.92	46.92	46.91	46.88	46.86	46.84	46.83	46.81	46.78	47.10	47.11	47.10	47.08	47.07	47.06	47.04	47.01	46.98	46.96	46.95	46.92	46.90	46.90	46.89	46.86
Indian Promoter	46.64	46.64	46.62	46.59	46.58	46.55	46.54	46.53	46.50	46.82	46.83	46.82	46.80	46.79	46.77	46.76	46.73	46.70	46.68	46.67	46.64	46.62	46.62	46.61	46.57
Foreign Promoter	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28	0.28
Institutions	39.23	40.17	40.50	40.34	40.46	40.69	40.41	40.39	41.85	41.45	41.44	43.36	42.52	43.30	44.42	45.84	46.05	46.10	46.60	46.79	46.88	46.81	47.06	47.07	47.03
Mutual Funds / UTI	10.14	11.94	12.58	13.21	13.05	11.43	13.33	13.26	15.72	15.86	16.44	16.47	16.96	17.00	16.71	18.92	16.82	16.23	16.89	16.92	17.55	19.35	20.57	18.01	16.93
FI/Bank/Insurance	5.94	6.56	7.17	7.75	9.03	10.25	11.04	11.50	11.12	10.96	11.10	11.53	11.87	11.98	12.40	9.84	10.02	9.56	7.24	6.41	6.34	4.64	4.48	5.59	6.12
Govt	0.28	0.29	0.29	0.29	0.29	0.28	0.28	0.28	0.29	0.29	0.00	-	-	-	-	0.01	0.01	0.01	0.01	0.01	0.01	-	-	-	-
FII	22.68	21.31	20.35	18.97	17.87	18.60	15.66	15.28	14.65	14.27	13.81	13.98	13.32	13.93	14.99	16.11	18.29	19.32	21.50	22.04	21.46	21.25	20.50	21.50	21.70
Other Institutions	0.19	0.08	0.11	0.11	0.21	0.13	0.09	0.07	0.07	0.07	0.09	1.39	0.37	0.38	0.31	0.96	0.92	0.98	0.97	1.40	1.52	1.56	1.50	1.98	2.27
Non-Institution	13.85	12.91	12.60	12.79	12.69	12.47	12.76	12.79	11.37	11.45	11.45	9.53	10.40	9.64	8.52	7.11	6.93	6.92	6.44	6.26	6.20	6.28	6.06	6.03	6.11
Bodies Corporate	0.71	0.77	0.59	0.52	0.50	0.46	0.52	0.76	0.74	0.83	0.73	0.72	0.55	0.44	0.41	0.40	0.39	0.31	0.32	0.30	0.30	0.28	0.24	0.24	0.26
Others (incl. Retail) No. of shareholders	13.14 2,89,803	12.14 2,76,365	12.01 2,72,037	12.27 2,97,697	12.19 2,91,875	12.01 3,00,326	12.24 3,59,277	12.03 3,59,979	10.63 3,76,699	10.62 3,80,987	10.72 3,76,199	8.81 3,58,915	9.85 3,46,431	9.20 3,20,997	8.11 2,87,413	6.71 2,79,810	6.54 2,78,410	6.61 2,86,746	6.12 2,77,269	5.96 2,79,907	5.90 2,81,132	6.00 2,84,551	5.82 2,78,295	5.79 2,86,959	5.85 2,88,330

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	SHI: Biotech	14.9%	2 / 15
2	Nifty Pharma	6.18%	5 / 20
3	Nifty Healthcare	5.3%	7 / 20
4	Nifty Midcap 50	2.46%	12 / 50
5	Nifty Midcap 100	1.65%	13 / 100
6	Nifty Midcap 150 Momentum 50	1.46%	30 / 50
7	Nifty Midcap 150	1.37%	13 / 149
8	NIFTY Large Midcap 250	0.71%	26 / 250
9	Nifty 500	0.28%	80 / 499
10	Nifty Total Market	0.27%	80 / 749

Prominent Investor Holdings

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Lupin Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Dr. Kamal K Sharma Designated Person	September-2021	Market Sale (Disposal) 9th Sep 2021	0.04 %	₹ 985.00	15.00 k	₹ 1.48 cr
Nilesh D. Gupta Promoter	August-2021	Market Purchase (Acquisition) 27th Aug 2021	0.20 %	₹ 943.58	5.30 k	₹ 50.01 lac
Sunil Makharia Designated Person	August-2021	Market Sale (Disposal) 18th Aug 2021	0.00 %	₹ 974.00	20.00 k	₹ 1.95 cr
Ramesh Swaminathan Designated Person	August-2021	Market Sale (Disposal) 16th Aug 2021	0.00 %	₹ 978.00	10.00 k	₹ 97.80 lac
Mr. Sunil Makharia Designated Person	June-2021	Market Sale (Disposal) 30th Jun 2021	0.01 %	₹ 1,161.00	2.00 k	₹ 23.22 lac
Mr. Naresh Gupta Designated Person	June-2021	Market Sale (Disposal) 30th Jun 2021	0.01 %	₹ 1,163.05	3.00 k	₹ 34.89 lac
Mr. Debabrata Chakravorty Designated Person	June-2021	Market Sale (Disposal) 30th Jun 2021	0.00 %	₹ 1,158.30	3.00 k	₹ 34.75 lac
Ms. Minaxi Bhatt Designated Person	June-2021	Market Sale (Disposal) 24th Jun 2021	0.00 %	₹ 1,126.65	1.00 k	₹ 11.27 lac
Mr. Jon Stelzmiller Designated Person	June-2021	Market Sale (Disposal) 23rd Jun 2021	0.00 %	₹ 1,123.13	1.23 k	₹ 13.76 lac
Mr. Naresh Gupta Designated Person	June-2021	Market Sale (Disposal) 23rd Jun 2021	0.01 %	₹ 1,150.15	500.00	₹ 5.75 lac

…

Corporate Actions

History of Lupin Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 12/share
Record date: 25th Jul 2025Ex-date: 25th Jul 2025
Announced on: 15th May 2025
Dividend₹ 8/share
Record date: 16th Jul 2024Ex-date: 16th Jul 2024
Announced on: 6th May 2024
Dividend₹ 4/share
Record date: 14th Jul 2023Ex-date: 14th Jul 2023
Announced on: 4th Jul 2023
Dividend₹ 4/share
Record date: 15th Jul 2022Ex-date: 14th Jul 2022
Announced on: 18th May 2022
Dividend₹ 6.50/share
Record date: 28th Jul 2021Ex-date: 27th Jul 2021
Announced on: 13th May 2021

Company Profile

Overview of Lupin Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Lupin Limited is a pharmaceutical company, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates in India and the United States...

Key personnel

Dr. Fabrice Egros

President - Corporate Development

Mr. Spiro Gavaris

President - US Generics

Mr. Claus Jepsen

President - Global Specialty

Dr. Cyrus Karkaria

President - Biotech Business

Mr. Yashwant (Yash) Mahadik

President - Global Human Resources

Dr. Sofia Mumtaz

President - Legal and Compliance, Canada, ANZ and NEA Business

Mr. Rajeev Sibal

President - India Region Formulations

Mr. Abdelaziz Toumi

Chief Executive Officer of Lupin Manufacturing Solutions Limited

View all

Incorporated on

01 Mar 1983

Last Annual

31 Mar 2026

Last Interim

31 Mar 2026

No. of Employees

IPO date

30 Nov 1994

Free Float

24,22,17,662

Website

https://www.lupin.com/

Phone no.

+912266402323

Address

3rd Floor, Kalpataru Inspire,, Off. Western Expressway Highway,, Santacruz (East),, MUMBAI, 400055, India

Frequently Asked Questions

What is the current share price of Lupin Ltd.?

The current share price of Lupin Ltd. is ₹ 2,460.60 as of 3 Jul 2026.

What is the market capitalisation of Lupin Ltd.?

The market capitalisation of Lupin Ltd. stands at ₹ 1,09,718.00 Cr.

What is the PE ratio of Lupin Ltd.?

The Price-to-Earnings (PE) ratio of Lupin Ltd. is 20.57 as of the latest trailing twelve months data.

What is the ROE and ROCE of Lupin Ltd.?

Lupin Ltd. has a Return on Equity (ROE) of 26.90% and a Return on Capital Employed (ROCE) of 26.16% as per the latest financial reports.

What is the 52-week high and low of Lupin Ltd.?

The 52-week high of Lupin Ltd. is - and the 52-week low is -.

What is the dividend yield of Lupin Ltd.?

The dividend yield of Lupin Ltd. is 0.50% based on the current market price.

What is the FII and DII holding in Lupin Ltd.?

Foreign Institutional Investors (FII) hold 21.70%, Domestic Institutional Investors (DII) hold 23.05% and retail/public investors hold 5.85% of Lupin Ltd. shares.

What sector does Lupin Ltd. belong to?

Lupin Ltd. operates in the Healthcare sector. 44.44% of analysts have a Buy or Strong Buy rating on Lupin Ltd. with a consensus target price of ₹ 2,500.00, implying 4.18% upside from current levels.

What is the beta of Lupin Ltd.?

The beta of Lupin Ltd. is 0.55, indicating its price volatility relative to the broader market. Over the past 1 year, Lupin Ltd. has delivered an absolute return of 24.28%.

What is the RSI of Lupin Ltd.?

The 14-day Relative Strength Index (RSI) of Lupin Ltd. is 63.22, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.

Lupin Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Lupin Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Holdings and Presence

Company Profile

Corporate Actions